
Onesource Specialty Pharma Share Price: What Could the Next 3 Years Look Like?
Onesource Specialty Pharma share price Rs 1,658 (10 July 2026). 52W high Rs 2,088, low Rs 1,057. Market cap Rs 19,005 Cr. 2030 scenario range Rs 1,810 to Rs 2,990.
Updated: 13 Jul 2026 • 5:39 pm
Posted by:

The Onesource Specialty Pharma share price forecast for the next 3 years is a question on many investors' minds as the stock trades at Rs 1,658 on 10 July 2026, within a 52 week range of Rs 1,057 to Rs 2,088. This article lays out a scenario based Onesource Specialty Pharma share price outlook for 2027, 2028 and 2030, built on the company's fundamentals, sector trends and the key risks that could change the trajectory. Rather than a single number, the focus here is on the range of outcomes and the assumptions behind each one.
Click Here – Get Free Investment Predictions
Onesource Specialty Pharma Company Overview
Onesource Specialty Pharma is a contract development and manufacturing company focused on complex injectables, ophthalmics and specialty formulations for global pharma clients, demerged from Strides Pharma. Understanding the business model is the first step in framing any credible Onesource Specialty Pharma share price forecast, because the durability of earnings ultimately decides where the stock trades.
| Company | Onesource Specialty Pharma |
| NSE Ticker | ONESOURCE |
| CMP (10 July 2026) | Rs 1,658 |
| 52 Week High | Rs 2,088 |
| 52 Week Low | Rs 1,057 |
| Market Cap | Rs 19,005 Cr |
| Stock PE | NA |
| Book Value | Rs 509 |
| ROE | 1.09% |
| ROCE | 0.57% |
| Dividend Yield | 0% |
Where Does Onesource Specialty Pharma Share Price Stand Today?
The stock currently trades about 21 percent below its 52 week high of Rs 2,088, which means the market has already tempered some of its optimism. For anyone building a Onesource Specialty Pharma share price forecast, this correction matters for the Onesource Specialty Pharma share price forecast starting point, because entry valuations have a large bearing on 3 year returns.
At the current price, Onesource Specialty Pharma commands a market capitalisation of Rs 19,005 Cr and trades at a price to earnings multiple of NA. The company generates a return on equity of 1.09% and a return on capital employed of 0.57%, which places it in the category of businesses with a recovering profitability profile. These numbers anchor the Onesource Specialty Pharma share price forecast scenarios that follow. How the broader Nifty 50 index trades over this period will also influence the multiple investors are willing to assign to the stock.
Onesource Specialty Pharma Share Price Forecast: Key Growth Drivers for the Next 3 Years
Four forces are likely to shape the Onesource Specialty Pharma share price forecast between now and 2030, and together they explain most of the dispersion in this Onesource Specialty Pharma share price forecast. Each is discussed below with its likely direction of impact.
Earnings Trajectory and Return Ratios
Stock prices ultimately follow earnings. With a recovering profitability profile at present, the pace at which profits compound over FY27 to FY30 will be the single biggest determinant of the Onesource Specialty Pharma share price forecast actually playing out. Consistent earnings delivery tends to expand valuation multiples, while misses compress them quickly.
Structural Tailwinds in Indian Pharmaceuticals
The Indian pharmaceutical market continues to grow in high single to low double digits, supported by chronic disease prevalence, better diagnosis rates and premiumisation of therapies. Companies with strong brand equity and field force productivity, like Onesource Specialty Pharma, are positioned to grow ahead of the market. Sector trends are visible in the Nifty Pharma index, which serves as a useful barometer for the space.
Within the space, investors often benchmark Onesource Specialty Pharma against peers such as Divis Laboratories, Piramal Pharma and Gland Pharma on growth and valuations before forming a view on the Onesource Specialty Pharma share price forecast.
Company Specific Catalysts
The bull case for Onesource Specialty Pharma rests on rising global CDMO outsourcing of complex injectables and a specialised manufacturing capability that is hard to replicate. If these play out on schedule, the Onesource Specialty Pharma share price forecast for 2030 could gravitate toward the upper end of the scenario range discussed below.
Macro Environment and Liquidity
The RBI rate cycle, FII flows into Indian equities and overall market valuations will influence the multiple investors are willing to pay. A benign macro backdrop supports the optimistic end of any Onesource Specialty Pharma share price forecast, while global risk aversion would do the opposite to the Onesource Specialty Pharma share price outlook.
Onesource Specialty Pharma Share Price Forecast 2027, 2028 and 2030: Scenario Analysis
The table below presents a scenario based Onesource Specialty Pharma share price forecast using compounded annual growth assumptions applied to the current market price of Rs 1,658. These are illustrative ranges, not point predictions, and actual outcomes can fall outside them.
| Year | Bear Case | Base Case | Bull Case | Assumption |
|---|---|---|---|---|
| 2027 | Rs 1,710 | Rs 1,860 | Rs 2,020 | 2% to 14% CAGR on CMP |
| 2028 | Rs 1,740 | Rs 2,010 | Rs 2,300 | 2% to 14% CAGR on CMP |
| 2030 | Rs 1,810 | Rs 2,340 | Rs 2,990 | 2% to 14% CAGR on CMP |
In the base case scenario of this Onesource Specialty Pharma share price forecast, the 2030 level works out to roughly Rs 2,340, implying steady compounding from today's levels. The bull case of Rs 2,990 assumes rising global CDMO outsourcing of complex injectables and a specialised manufacturing capability that is hard to replicate delivers ahead of expectations, while the bear case of Rs 1,810 captures a scenario where growth stalls. That is an outcome band of about 9 percent to 80 percent over the period.
Consult a SEBI Registered Investment Advisor Before Acting on Any Forecast
Bull Case vs Bear Case for Onesource Specialty Pharma Share Price
The Bull Case
The optimistic Onesource Specialty Pharma share price forecast assumes rising global CDMO outsourcing of complex injectables and a specialised manufacturing capability that is hard to replicate. Combined with supportive sector conditions, this could lift both earnings and the valuation multiple, pushing the stock toward Rs 2,990 by 2030.
The Bear Case
The cautious view centres on the fact that client concentration and the capital intensity of specialty manufacturing facilities are key considerations. If these pressures dominate, the Onesource Specialty Pharma share price forecast would skew toward the lower band and the stock could stagnate near Rs 1,810 even by 2030, underperforming broader indices.
Key Risks That Could Change the Onesource Specialty Pharma Share Price Outlook
- Execution risk: Delays in strategy execution or capacity plans would push the earnings trajectory below the base case assumed in this Onesource Specialty Pharma share price forecast.
- Valuation risk: At a PE of NA, any earnings disappointment can trigger sharp multiple compression before fundamentals stabilise.
- Sector risk: Client concentration and the capital intensity of specialty manufacturing facilities are key considerations.
- Macro risk: A global slowdown, adverse FII flows or unexpected rate moves would compress equity valuations across the market.
- Regulatory risk: Policy, tax or compliance changes affecting the sector can alter the earnings outlook with little warning.
Is Onesource Specialty Pharma Worth Watching for the Long Term?
For long term investors, the relevant question is not just where the Onesource Specialty Pharma share price forecast lands in 2030 or what any single Onesource Specialty Pharma share price forecast says today, but whether the business can compound capital through cycles. The company's positioning around rising global CDMO outsourcing of complex injectables and a specialised manufacturing capability that is hard to replicate gives it a credible growth story, while the risks outlined above define what must be monitored each quarter.
Investors should track quarterly earnings, management commentary and sector data rather than anchoring to any single number from a Onesource Specialty Pharma share price outlook. Historically, staying focused on business fundamentals has served investors better than chasing price targets, and consulting a SEBI registered advisor before investing remains the prudent approach.
Download the Univest iOS App or Univest Android App to track Onesource Specialty Pharma share price live.
Conclusion
The Onesource Specialty Pharma share price forecast for the next 3 years spans Rs 1,810 to Rs 2,990 by 2030 under the scenarios discussed, with a base case near Rs 2,340. Any credible Onesource Specialty Pharma share price forecast must be updated as facts change, and the path will be decided by earnings delivery, rising global CDMO outsourcing of complex injectables and a specialised manufacturing capability that is hard to replicate and the broader market environment. Treat these ranges as a framework for thinking, not a promise of outcomes, and revisit the assumptions as new results come in. Consult a SEBI registered investment advisor before making any investment decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What is the Onesource Specialty Pharma share price forecast for the next 3 years?
Ans. The Onesource Specialty Pharma share price forecast for the next 3 years is scenario based rather than a single number. By 2030, the illustrative range spans Rs 1,810 in the bear case to Rs 2,990 in the bull case, with a base case near Rs 2,340, depending on earnings delivery and market conditions.
What is the Onesource Specialty Pharma share price forecast for 2027?
Ans. For 2027, the scenario range works out to Rs 1,710 to Rs 2,020, with a base case around Rs 1,860. This assumes compounding on the current price of Rs 1,658 and is illustrative, not a guaranteed outcome.
What is the Onesource Specialty Pharma share price forecast for 2028?
Ans. The 2028 scenario range is Rs 1,740 to Rs 2,300, with the base case near Rs 2,010. Actual levels will depend on earnings growth, sector trends and overall market valuations at the time.
What is the current share price of Onesource Specialty Pharma?
Ans. As of 10 July 2026, Onesource Specialty Pharma trades at around Rs 1,658 on the NSE, within a 52 week range of Rs 1,057 to Rs 2,088. Prices change continuously during market hours, so check live quotes before acting.
Is Onesource Specialty Pharma a good stock for the long term?
Ans. Onesource Specialty Pharma has a credible long term story built on rising global CDMO outsourcing of complex injectables and a specialised manufacturing capability that is hard to replicate, but it also carries risks since client concentration and the capital intensity of specialty manufacturing facilities are key considerations. Long term suitability depends on your risk profile and portfolio, so consult a SEBI registered investment advisor before investing.
What is the Onesource Specialty Pharma share price outlook for 2030?
Ans. The Onesource Specialty Pharma share price outlook for 2030 spans Rs 1,810 to Rs 2,990 across bear and bull scenarios. Where the stock actually lands will be driven by profit growth, valuation multiples and macro conditions closer to that date.
What are the key risks to the Onesource Specialty Pharma share price forecast?
Ans. The main risks are execution delays, valuation compression from the current PE of NA, sector specific pressures, macro shocks and regulatory changes. Any of these can push the stock below the base case scenario discussed in this article.
Recent Articles

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs ICICI Prudential R.I.G.H.T. IDCW: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Direct IDCW: NAV, Returns and Maturity Status Compared
28 July 2026

Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Regular Growth: NAV, Returns and Maturity Status Compared
28 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs ICICI Prudential R.I.G.H.T. IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Direct IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared
Popular this week
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs Bank of India Mid Cap Tax Fund Series 1 Direct IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs ICICI Prudential R.I.G.H.T. IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Direct IDCW: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan vs Bank of India Mid Cap Tax Fund Series 2 Regular Growth: NAV, Returns and Maturity Status Compared
Sundaram Long Term Micro Cap Tax Advantage Fund Series III Regular Plan IDCW Payout vs ICICI Prudential Wealth Enhancement Fund: NAV, Returns and Maturity Status Compared

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





